Research map: Clinical implications of zolbetuximab-associated hypoalbuminemia in CLDN18.2-positive gastric or gastroesophageal junction cancer

Back to the article

Papers in this map

  1. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics · Yoshinobu Kanda · 2012 · 19329 citations · Cited by this paper
  2. Zolbetuximab plus pembrolizumab and chemotherapy in CLDN18.2-positive, HER2-negative, PD-L1-positive gastric or gastroesophageal junction adenocarcinoma: randomized, double-blind, phase III LUCERNA trial · 2026 · Related
  3. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up · Florian Lordick · 2022 · 1526 citations · Cited by this paper
  4. Early-onset biliary tract cancers: clinical and molecular insights · 2026 · Related
  5. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial · Kohei Shitara · 2023 · 826 citations · Cited by this paper
  6. A prospective, multicenter, observational study of trastuzumab deruxtecan in elderly patients with HER2-positive gastric cancer: EN-COURAGE · 2026 · Related
  7. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial · Manish A. Shah · 2023 · 657 citations · Cited by this paper
  8. Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study · 2026 · Related
  9. Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development · Uğur Şahin · 2008 · 505 citations · Cited by this paper
  10. Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study · 2026 · Related
  11. Gastric cancer · Raghav Sundar · 2025 · 377 citations · Cited by this paper
  12. Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer · 2026 · Related
  13. Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals · Özlem Türeci · 2011 · 123 citations · Cited by this paper
  14. The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors · 2026 · Related
  15. Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma · Kohei Shitara · 2024 · 97 citations · Cited by this paper
  16. BevRam-GC01 study protocol: a phase I trial of bevacizumab plus ramucirumab and paclitaxel in advanced gastric cancer · 2026 · Related
  17. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma · Kohei Shitara · 2024 · 90 citations · Cited by this paper
  18. Incidence, treatment variation, and survival of synchronous head and neck and esophageal carcinomas: a descriptive nationwide cohort study in the Netherlands · 2026 · Related
  19. The dawn of precision medicine in diffuse-type gastric cancer · Akira Ooki · 2022 · 48 citations · Cited by this paper
  20. Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal dissemination · Haruki Ogawa · 2024 · 42 citations · Cited by this paper
  21. Effect of antiemetics on zolbetuximab-induced gastric injury and emesis in ferrets · Fumitaka Kinugasa · 2024 · 31 citations · Cited by this paper
  22. Two cases of protein-losing enteropathy induced by zolbetuximab in patients with unresectable advanced gastric cancer · Yoshitomo Yanagimoto · 2025 · 19 citations · Cited by this paper
  23. Modeling and addressing on-target/off-tumor toxicity of claudin 18.2 targeted immunotherapies · Elizabeth J. Carstens · 2025 · 19 citations · Cited by this paper
  24. Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer · K. Yamamoto · 2025 · 18 citations · Cited by this paper
  25. Imaging of Gastric Carcinomatosis · Raquel Saiz Martínez · 2021 · 17 citations · Cited by this paper
  26. Zolbetuximab-related gastritis: a case report of the patient with prolonged gastrointestinal symptoms · Yuya Sugiyama · 2025 · 16 citations · Cited by this paper
  27. On-target off-tumor toxicity of claudin18.2-directed CAR-T cells in preclinical models · Filippo Birocchi · 2025 · 15 citations · Cited by this paper
  28. Practical Management of Zolbetuximab Administration: The Project VYLOY Initiative · Yukiya Narita · 2025 · 12 citations · Cited by this paper
  29. Case Report: Zolbetuximab-induced gastritis with protein-losing gastroenteropathy and hypogammaglobulinemia: a case implicating IgA vasculitis · Yasuhiro Mitsui · 2025 · 11 citations · Cited by this paper
  30. Population PK and Exposure‐Response Analyses of Zolbetuximab in Patients With Locally Advanced Unresectable or Metastatic G/ GEJ Adenocarcinoma · Akihiro Yamada · 2025 · 10 citations · Cited by this paper
  31. Impact and effective management of nausea/vomiting on patients treated with zolbetuximab + chemotherapy: insights from the phase III SPOTLIGHT and GLOW studies · Kouhei Shitara · 2026 · 8 citations · Cited by this paper
  32. 42P Antitumor activity of zolbetuximab combined with chemotherapy and anti-mouse PD-1 antibody (anti-mPD-1) in a syngeneic mouse model and a virtual preclinical trial using a quantitative systems pharmacology (QSP) model · T. Nakayama · 2022 · 7 citations · Cited by this paper
  33. A case of zolbetuximab-induced protein-losing gastroenteropathy in a patient with advanced gastric cancer · Kunihiro Tsuji · 2025 · 4 citations · Cited by this paper
  34. A Mucosal Change like Hypertrophic Gastritis Following Zolbetuximab-Based Therapy in a Conversion Surgery Case of Advanced Gastric Cancer · Soshi Oyama · 2025 · 4 citations · Cited by this paper
  35. Safety and efficacy of zolbetuximab plus chemotherapy for claudin 18 isoform 2-positive advanced gastric cancer: initial report of real-world experience · Keitaro Shimozaki · 2025 · 4 citations · Cited by this paper
  36. Zolbetuximab-based chemotherapy in CLDN18.2-positive gastric cancer: real-world tumor response and early albumin kinetics · Yuki Ushimaru · 2026 · 2 citations · Cited by this paper
  37. Untitled · Cited by this paper

Source: OpenAlex (CC0)